US 12,110,290 B2
Triazolopyridinyl compounds as kinase inhibitors
Guanglin Luo, Newtown, PA (US); Jie Chen, Cambridge, MA (US); Carolyn Diane Dzierba, Medford, MA (US); David B. Frennesson, Naugatuck, CT (US); Junqing Guo, Princeton, NJ (US); Amy C. Hart, Littleton, CO (US); Xirui Hu, Cambridge, MA (US); Michael E. Mertzman, New Hope, PA (US); Matthew Reiser Patton, Cambridge, MA (US); Jianliang Shi, Furlong, PA (US); Steven H. Spergel, Warrington, PA (US); Brian Lee Venables, Durham, CT (US); Yong-Jin Wu, Madison, CT (US); Zili Xiao, East Windsor, NJ (US); and Michael G. Yang, Narberth, PA (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
Filed on Jul. 6, 2023, as Appl. No. 18/347,703.
Application 18/347,703 is a continuation of application No. 17/503,516, filed on Oct. 18, 2021, granted, now 11,767,322.
Claims priority of provisional application 63/093,463, filed on Oct. 19, 2020.
Prior Publication US 2024/0109888 A1, Apr. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) 14 Claims
 
1. A compound having formula (I), or salt thereof,

OG Complex Work Unit Chemistry
wherein
R1 is H, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, C1-3 deuteroalkyl, C1-3 deuteroalkoxy, halo, or cyclopropyl;
R2 is H, or halo;
R3 is H, halo, C1-3 alkyl or C1-3 deuteroalkyl;
R4 is H or F;
R5a and R5b are each H;
one of R6a and R6b is H and the other is F;
R7a and R7b are each, independently, H, deuterium, OH, F, C1-2 alkyl, or C1-2 haloalkyl;
R8 is H, F, Cl, C1-3 alkyl, C1-3 alkoxy, C1-3 deuteroalkyl, or C1-3 deuteroalkoxy;
R9 is H or CH3;
ring Z is phenyl;
Y is F, Cl, C1-3 alkyl, C1-3 alkoxy, CN, C1-3 haloalkyl, C1-3 haloalkoxy, C1-3 deuteroalkyl, C1-3 deuteroalkoxy, C(O)OCH3, or C═CH; and
n is 0, 1, 2, or 3.